Life
FDA Faces New Challenges Following Prasad's Departure
The recent exit of Prasad from the FDA raises questions about the agency's stability as it prepares for the introduction of generic Ozempic.
Editorial Staff
1 min read
The departure of Prasad from the FDA introduces a notable disruption within the agency, which is already navigating significant transitions.
As the FDA gears up for the market entry of generic Ozempic, the implications for drug approval processes and market dynamics are considerable.
This situation underscores the need for robust operational frameworks to ensure continuity and efficiency in regulatory practices amidst leadership changes.